6 results
Primary objective is to assess differences in endogenous hypoxia markers (CA9, PAI-1, VEGF [Rademakers et al. 2008]) and autophagy (LC3b [Rouschop et al. 2010]) before and after short-term pre-surgical treatment with HCQ in breast cancer patients.…
Primary: To demonstrate that high (100%) stimulation of ONS therapy reduces the mean attack frequency (MAF) in MICCH by at least 35% compared to low (30%) stimulation of ONS.Secondary: To evaluate • the rate of responders (>= 50% reduction in…
Primary objective: To determine the efficacy of the combination of acalabrutinib and venetoclax without obinutuzumab (AV; Arm A), or with obinutuzumab (AVG; Arm B) compared with chemoimmunotherapy (fludarabine/cyclophosphamide/rituximab [FCR]/…
Primary objective• To evaluate efficacy of acalabrutinib/venetoclax (AV) in terms of undetectable minimal residual disease (uMRD) response in bone marrow (BM) after 26 cycles of treatment in patients with CLL previously treated with venetoclax and…
Therapy:The investigational product, ACP-196, will be supplied as hardgelatin capsules for oral administration.Commercially available ibrutinib (IMBRUVICA®) will be used asthe reference therapy.Objectives: Primary Objective:To assess whether ACP-196…
The aim is thereby to reduce the risk of serious infections and the need for regular CLL treatment.